| DIRECT COMPETITOR COMPARISON | |
| GTCB | BAX | Pvt1 | TLCR | Industry | | Market Cap: | 25.73M | 33.99B | N/A | 2.70B | 107.08M | | Employees: | 109 | N/A | 10,0001 | 4,650 | 59 | | Qtrly Rev Growth (yoy): | -74.40% | 10.80% | N/A | 12.90% | 19.70% | | Revenue (ttm): | 2.64M | 12.56B | 3.14B1 | 1.54B | 13.84M | | Gross Margin (ttm): | 33.01% | 52.18% | N/A | 40.48% | 66.58% | | EBITDA (ttm): | -32.52M | 3.58B | N/A | 314.03M | -12.25M | | Oper Margins (ttm): | -1,317.62% | 23.53% | N/A | 18.66% | -158.08% | | Net Income (ttm): | -32.33M | 2.21B | N/A | 163.25M | N/A | | EPS (ttm): | -3.107 | 3.591 | N/A | 1.890 | -0.31 | | P/E (ttm): | N/A | 15.70 | N/A | 11.90 | 17.08 | | PEG (5 yr expected): | N/A | 1.12 | N/A | 1.08 | 1.15 | | P/S (ttm): | 9.73 | 2.71 | N/A | 1.75 | 9.82 |
|
| BAX = Baxter International Inc. | | Pvt1 = CSL Behring, LLC (privately held) | | TLCR = Talecris Biotherapeutics Holdings Corp. | | Industry = Biotechnology | | 1 = As of 2009 |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.21 | 0.00% | 56.92B | 12.69 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 54.09 | 0.00% | 15.64B | 18.10 | | Genzyme Corp. | GENZ | 54.87 | 0.00% | 14.56B | 31.28 | | Merck Serono S.A. | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.30 | 0.00% | 41.66B | 16.41 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 47.82 | 0.00% | 8.54B | 59.92 | | Teva Pharmaceutical Industries Limited | TEVA | 57.10 | 0.00% | 50.31B | 52.24 | | Sandoz International GmbH | Private - View Profile |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Watson Pharmaceuticals Inc. | WPI | 38.10 | 0.00% | 4.04B | 19.64 | | King Pharmaceuticals Inc. | KG | 11.44 | 0.00% | 2.84B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.68 | 0.00% | 5.40B | 108.47 | | Pfizer Inc. | PFE | 17.88 | 0.00% | 144.28B | 14.85 | | Johnson & Johnson | JNJ | 62.76 | 0.00% | 173.16B | 14.27 | | GlaxoSmithKline plc | GSK | 38.47 | 0.00% | 97.52B | 12.91 | | Sanofi-Aventis | SNY | 36.29 | 0.00% | 94.76B | N/A | | Novartis AG | NVS | 53.58 | 0.00% | 121.69B | 16.04 | | RHHBY.PK | 41.50 | 0.00% | N/A | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | AstraZeneca plc | AZN | 44.11 | 0.00% | 64.00B | 8.50 | | Abbott Laboratories | ABT | 53.35 | 0.00% | 82.52B | 14.44 | | Bristol-Myers Squibb Company | BMY | 24.25 | 0.00% | 48.04B | 4.51 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | BAX | | Becton Recalls Catheters
Tue 3:49pm -
Zacks.com | | • | BAX | | Germany Cancels Swine Flu Vaccines
Tue 10:52am -
at BusinessWeek | | • | BAX | | Cloning the Activist Masters' Portfolios
Tue 1:21am -
at Seeking Alpha | | • | BAX | | New Device Promises To Make Heart Surgery Easier And Safer
Fri, Feb 5 -
Investor's Business Daily | | • | BAX | | Baxter lobbying budget tops $1 million for 4Q
Fri, Feb 5 -
AP | | • | TLCR | | Talecris Biotherapeutics Receives Orphan Drug Designation for Aerosolized Alpha1-Proteinase Inhibitor to Treat Alpha1-Antitrypsin Deficiency
Fri, Feb 5 -
Business Wire | | • | BAX | | Baxter Downgraded
Fri, Feb 5 -
Zacks.com | | • | TLCR | | A Drugless Drugmaker IPO!
Thu, Feb 4 -
at Motley Fool | | • | BAX | | 3 Best Hedge Fund Healthcare Ideas
Wed, Feb 3 -
at Seeking Alpha | | • | BAX | | Home Health Care And Diagnostics Companies High Target Environment For Acquisitions According To RBC Capital Markets Expert Equity Analyst
Wed, Feb 3 -
Wall Street Transcript | | • | BAX | | Haemonetics Misses Zacks Estimate
Tue, Feb 2 -
Zacks.com | | • | BAX | | You Can't Afford This Huge Mistake
Tue, Feb 2 -
at Motley Fool | | • | TLCR | | Stephen Simpson Of Northland Securities Picks 4 Health Care Stock Winners For 2010
Wed, Jan 27 -
Wall Street Transcript | | • | TLCR | | HiSeq 2000 Genomics System Begins New Generation Of Innovation In DNA Sequencing Sector Of Biotech And Medical Diagnostics Industry
Mon, Jan 25 -
Wall Street Transcript | | • | TLCR | | After A Sluggish Year, VCs Eye Improvement
Fri, Jan 8 -
Investor's Business Daily | | | All Headlines for these symbols... |
|
|
|
1.52% Nasdaq 0.00%
Competitors
